RxDoctor Payments Data

Sajan Rao, MD

Cardiovascular Disease · Naples, FLNPI 1851589162

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for cardiovascular disease clinicians in FL, where the typical reported total is $2,774.

$873in general payments, 2019–2025

Across 8 payments — averaging $109.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$142
  • Medtronic$125
  • Edwards Lifesciences$125
  • Boston Scientific$111
  • Abiomed$103
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$102
  • plus $165 from 2 others
$102,352in research payments, 2019–2025

Across 77 payments — averaging $1329.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bayer$42K
  • Novartis$38K
  • Esperion Therapeutics, Inc.$23K

What the payments were for

  • Food & beverage$873100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$873 in reported general payments places this provider in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida →

Medicare billing

Part B allowed, 2024
$113,344
Medicare patients
276
Services billed
1,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis32$1,191,889
EliquisApixaban172$239,680
Repatha SureclickEvolocumab110$118,812
FarxigaDapagliflozin Propanediol100$115,642
EntrestoSacubitril/Valsartan69$88,111
XareltoRivaroxaban41$50,769
MounjaroTirzepatide36$37,316
OzempicSemaglutide17$31,827
Praluent PenAlirocumab12$14,940
WegovySemaglutide11$14,134
VascepaIcosapent Ethyl11$10,012
Eplerenone103$8,410
Ezetimibe161$6,240
Candesartan Cilexetil47$5,509
Rosuvastatin Calcium185$3,974

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Naples

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →